Responding to RFA-DA-10-009, this application seeks renewal of the Pacific Region Node of the National Drug Abuse Treatment Clinical Trials Network (CTN) to continue improving the quality and delivery of addiction treatments that can be implemented efficiently by community-based treatment providers (CTPs). The ongoing and future research, training, and dissemination activities of the Pacific Region Node, led by Walter Ling, M.D., will serve the CTN mission """"""""to improve the quality of drug abuse treatment throughout the country, using science as a vehicle."""""""" The Node will continue to contribute significantly to the CTN effort by its leadership and participation in innovative concept development, rigorous conduct of research, efficient management, and effective dissemination of CTN products. In the most recent funding period, for example, Node participants developed two protocols and currently lead protocol development of CTN0048, Cocaine Use Reduction with Buprenorphine (CURB). Node personnel will continue to develop and disseminate training materials and manuals for use across the CTN, to plan and host CTN-oriented conferences, and disseminate CTN-based findings through trainings, presentations, publications, and Internet-based methods. The Node's activities will advance the science and increase broad implementation of research-proven treatments in a collaborative manner with other nodes, CTN CTPs, and other providers and researchers worldwide. This renewal proposes adding two CTPs to the existing five, increasing geographic presence and racial/ethnic inclusion as well as ensuring access to every possible setting, modality, special population, and drug abuse problem. The Pacific Region Node intends to accelerate development and testing of new medications and behavioral therapies that can be integrated to achieve better outcomes. Innovation, research pacing, and relevance will be enhanced by increasing interaction with provider groups and with researchers examining potential therapies, exploiting the Node's existing partnerships while building new collaborations and involving more broad-based settings. Renewal of the Pacific Region Node will strengthen CTN efforts through collaborative work with NIDA, CTN participants, and other stakeholders.
To promote use of research-proven addiction treatments, the Pacific Region Node will continue its work to incorporate more broad-based settings for CTN research, resulting in greater inclusion of and service to populations that are not comprehensively served by traditional CTPs. The Node will continue collaboration with the overall CTN to identify and address addiction challenges, public health needs, and research issues.
|McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531|
|Garrett, Sharon B; Doyle, Suzanne R; Peavy, K Michelle et al. (2018) Age differences in outcomes among patients in the ""Stimulant Abuser Groups to Engage in 12-Step"" (STAGE-12) intervention. J Subst Abuse Treat 84:21-29|
|Tomko, Rachel L; Baker, Nathaniel L; McClure, Erin A et al. (2018) Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend 182:1-7|
|Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951|
|Zhu, Yuhui; Evans, Elizabeth A; Mooney, Larissa J et al. (2018) Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol 13:488-497|
|Crist, R C; Doyle, G A; Nelson, E C et al. (2018) A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 18:173-179|
|Crist, Richard C; Li, James; Doyle, Glenn A et al. (2018) Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse 44:431-440|
|Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032|
|Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80|
|Hser, Yih-Ing; Huang, David; Saxon, Andrew J et al. (2017) Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine?+?Naloxone and Methadone. J Addict Med 11:63-69|
Showing the most recent 10 out of 112 publications